Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

122 results about "Tissue transplantation" patented technology

Amine Compounds

InactiveUS20080200535A1Potent immunosuppressive actionBiocideSenses disorderUveitisAutoimmune disease
There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation.Novel amine compounds having an S1P1 / Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.
Owner:ASAHI KASEI PHARMA

Continuous noninvasive glucose monitoring in diabetic, non-diabetic, and critically ill patients with oct

New optical coherence tomography (OCT) techniques are disclosed which are designed to improve OCT glucose concentration measure accuracy and are capable of being performed on a continuous basis. New multi-wavelength optical coherence tomography (OCT) techniques are also disclosed and designed to reduce artifacts do to water. New optical coherence tomography (OCT) techniques are also disclosed for determining local profusion rates, local analyte transport rates and tissue analyte transport rates as a measure of tissue health, disease progression and state and tissue transplantation effectiveness.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Tissue transplantation method and apparatus

The present invention provides for the transplantation of tissue from a donor site in a body to a recipient site. The device includes an outer chamber having an interior volume in which a perforated inner chamber can be placed. During the aspiration of tissue, a vacuum is formed in the interior volume of the outer chamber, to draw tissue from a cannula into the perforated inner chamber. The perforations are sized such that fat is collected within the inner chamber, while fluids and other materials are drawn through the perforations, away from the collected fat. For reinjection, the inner chamber can be removed from the outer chamber, and a sleeve positioned to cover the perforations and thereby form a syringe body that can be interconnected to a needle and plunger for reinjection of the collected fat.
Owner:SHIPPERT ENTERPRISES

Vascularized tissue graft

The present invention relates generally to improved methods for tissue engineering including tissue transplantation, augmentation and regeneration. More particularly, the present invention provides a method for the generation of donor vascularized tissue suitable for use in tissue transplantation, augmentation and / or repair. The present invention further enables the use of a support matrix in the generation of an anatomical construct comprising the donor vascular tissue. The support matrix may be devised such that it has dimensions of a size and shape adapted to simulate those of tissue to be transplanted, augmented and / or repaired. In addition to its use in tissue repair, the methods and support matrix of the present invention may also find application as a means for delivering a desirable gene product to a subject. The method and support matrix of the present invention is conveniently be made available in the form of a kit, for use generally in the field of tissue engineering.
Owner:VICTORIAN TISSUE ENG CENT

Tissue transplantation compositions and methods

A biomedical material for transplant to a subject is provided according to embodiments of the present invention which includes an isolated donor tissue enzyme-treated to reduce the amount of proteoglycans in the donor tissue compared to untreated tissue. Isolated cells are optionally added to the enzyme-treated donor tissue, including leukocytes, particularly monocytes; macrophages; platelets; cells derived from an intervertebral disc such as chondrocyte-like nucleus pulposus cells; fibrocytes; fibroblasts; mesenchymal stem cells; mesenchymal precursor cells; chondrocytes; or a combination of any of these. The isolated donor tissue is articular cartilage or an intervertebral disc tissue such as nucleus pulposus tissue and / or annulus fibrosis tissue enzyme-treated to remove proteoglycans normally present in these tissues. A biomedical material of the present invention is administered to a subject to treat a disorder or injury, such as a disorder or injury to connective tissue.
Owner:FERREE BRET

System and method for transplantation of dermal tissue

A dermal tissue transplantation system combining a tissue particle harvester, a tissue particle collector, and a chambered dressing. The system provides a harvester capable of harvesting tissue from a donor site on the order of about 100 microns. The integrated tissue particle collector provides a means for collecting the harvested tissue for in situ cultivation in a chambered dressing at the wound site.
Owner:KCI LICENSING INC +1

System and method for transplantation of dermal tissue

A dermal tissue transplantation system combining a tissue particle harvester, a tissue particle collector, and a chambered dressing. The system provides a harvester capable of harvesting tissue from a donor site on the order of about 100 microns. The integrated tissue particle collector provides a means for collecting the harvested tissue for in situ cultivation in a chambered dressing at the wound site.
Owner:APPLIED TISSUE TECH +1

Vacsularized tissue for transplantation

Tissue engineering holds enormous potential to replace or restore function to a wide range of tissues. However, the most successful applications have been limited to thin avascular tissues in which delivery of essential nutrients occurs primarily by diffusion. Pursuant to the present invention, a prevascularized, thick tissue construct is created having a network of capillaries with lumens capable of nutrient and origin delivery and forming anastamoses to host vasculature. A tissue transplantation strategy is comprised of (1) in vitro vascularization of a tisue construct, (2) transplantation of prevascularized tissue to wound bed of host where vessels of implantable tissue and host rapidly anastomose, and (3) host-directed remodeling and reorganization of the tissue and vascular network.
Owner:RGT UNIV OF CALIFORNIA

Decellularization and recellularization apparatuses and systems containing the same

The invention described herein provides systems and apparatuses for an initial preparation of an organ or tissue scaffold comprising an extracellular matrix, and subsequent recellularization of the scaffold to ultimately form a resultant artificial organ or tissue incorporating the natural and original extracellular matrix. The techniques and equipment of the invention collectively minimize scaffold collapse, compression or physical damage to the organ as well as afford the advantages of significant maintenance of the initial natural structural and biochemical attributes of the organ or tissue. The invention is particularly useful in organ and tissue transplantation and repair.
Owner:MIROMATRIX MEDICAL

Therapeutic methods for treating vascular eye disorders with DII4 antagonists

InactiveUS20080181893A1Inhibition of developmentEnhanced regrowthSenses disorderPeptide/protein ingredientsDiabetic retinopathyIschemic retinopathy
A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor. The method of the invention is useful for treating eye disorders such as ischemic retinopathy, diabetic retinopathy, age related macular degeneration, corneal neovascularization, neovascular glaucoma, or retinopathy of prematurity. The method is also useful or treating ischemic or vascular disorders such as ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension.
Owner:REGENERON PHARM INC

Composition of labdane diterpenes extracted from andrographis paniculata, ufeful for the treatment of autoimmune diseases, and alzheimer disease by activation for ppr-gamma receptors

The diterpenic labdane 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,ha-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone, chemically diagrammed as inhibits the synthesis of pro-inflammatory cytokines, activates the PPAR-gamma receptor and diminishes nuclear factor kappa B. The compound is useful to treat auto-immune diseases, for organ and tissue transplantation, and to treat immunodeficiency (e.g., AIDS).
Owner:INNOBIOSCI

Combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion

A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The methos comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.
Owner:YEDA RES & DEV CO LTD

Preparation and clinical applications of cytokine-rich fat-derived stromal cell composite transplantation material

InactiveCN107224614AReduce scarringPromote tissue regeneration and repairFibrinogenPharmaceutical delivery mechanismBiomedical engineeringTransplanted tissue
The invention discloses the preparation and clinical application of a fat-derived stromal cell composite graft material rich in cytokines. The preparation method is through 1) the acquisition and purification of fat granules; 2) the acquisition of nano-fat stromal cells; 3) the biological characteristics and multi-directional differentiation identification of nano-fat-derived stem cells (NFSCs); 4) fibrin glue rich in cytokines The preparation of transplant materials in four steps is used for the clinical repair and correction of sunken deformities of the face, chest and other body surface soft tissues. The invention is based on the new technology of stromal vascular components to promote trauma or wound repair, reduce scar hyperplasia, promote tissue regeneration repair and organ reconstruction, shorten the recovery time of patients, improve the quality of rehabilitation, and achieve good curative effect. It is a clinically assisted autologous fat Tissue transplantation provides experimental basis and theoretical support for the repair of soft tissue or organ defects, burn wounds, refractory wounds, and breast reconstruction after breast cancer surgery.
Owner:黎洪棉

Preparation method and application of humanized CD28 gene remolding animal model

The invention discloses a preparation method and application of a humanized CD28 gene remolding animal model. The invention also provides a sgRNA sequence capable of specifically targeting the Cd28 gene, a method for preparing a multi-gene humanized animal model and related applications. According to the invention, a tool mouse suitable for transplantation of a humanized cell or tissue and a preparation method of a novel humanized animal model are provided, a research of related diseases is facilitated and an effective technical means is provided for the development of biomedical experiments.The invention also relates to remolding an non-human animal by using a humanized gene, in particular to remolding a rodent by using the gene. Particularly, remolding a mouse by using the gene relatesto the preparation method of the humanized CD28 gene remolding animal model and the application thereof in the field of biomedicine.
Owner:BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD

Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations

The present invention generally concerns methods and compositions for improving the immune system of an individual that is an immune-compromised individual. In particular aspects, the immune-compromised individual is elderly or is immunosuppressed, such as from chemotherapy or immunosuppressants following organ or tissue transplantation. In specific embodiments, the invention relates to delivery to the immune-compromised individual of immune complexes harboring an antigen and an antibody that immunologically recognizes the antigen. The antigen may be viral, bacterial, or fungal, for example.
Owner:BAYLOR COLLEGE OF MEDICINE

Heterocyclic Janus kinase 3 inhibitors

The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and / or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ / tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).
Owner:ASTELLAS PHARMA INC

Medical/Surgical Implant

The present invention relates to the field of implants. In particular, the present invention relates to an implant for tissue reconstruction which comprises a scaffold structure that includes a void system for the generation of prevascularized connective tissue with void spaces for cell and / or tissue transplantation. Moreover, the present invention relates to a method of manufacturing such an implant, to the internal architecture of such an implant, to a removal tool for mechanical removal of space-occupying structures from such an implant, to a kit comprising such an implant and such a removal tool, to a removal device for the removal of superparamagnetic or ferromagnetic space-occupying structures from such an implant, as well as to a guiding device for providing feedback to a surgeon during the procedure of introducing transplantation cells into the void spaces generated upon removal of space-occupying structures from such an implant.
Owner:KLINIKUM REKHTS DER IZAR DER TEKHNISHEN UNIV MYUNKHEN

Novel Method for the Preparation of Embryoid Bodies (Ebs) and Uses Thereof

ActiveUS20080019952A1No negative influence on the differentiation capacityCheap and simple methodBioreactor/fermenter combinationsBiocideGenomicsAssay
Provided are means and methods for producing embryoid bodies (EBs) from multi- or pluripotent cells. In particular, a method of generating embryoid bodies (EBs) is described comprising agitation of a liquid suspension culture of multi- or pluripotent cells in a container until generation of cell aggregates, optionally diluting the suspension, and further agitation of the suspension until formation of EBs. Furthermore, the present invention relates to the use of the novel culturing method and EBs obtained thereby for a variety of applications including genomics, diagnostic assays, teratogenic / embryotoxicological and pharmacological assays as well as for the provision of tissue grafts.
Owner:EVOTECH INT GMBH

Modular Assembly of Tissue Engineered Constructs

Scaleable, vascularised tissue constructs that are composed of a multiplicity of cell containing, discrete and separable modules, methods of fabricating same and uses thereof. The tissue construct is a tissue substitute used in tissue transplantation or substitution or for the purpose of in vitro mimic of normal tissue.
Owner:SEFTON MICHAEL V +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products